A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,700 shares of BEAM stock, worth $268,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,700
Previous 42,800 75.0%
Holding current value
$268,035
Previous $1 Million 73.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$22.57 - $33.14 $724,497 - $1.06 Million
-32,100 Reduced 75.0%
10,700 $262,000
Q2 2024

Aug 14, 2024

SELL
$21.22 - $32.66 $2.24 Million - $3.44 Million
-105,400 Reduced 71.12%
42,800 $1 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $3.48 Million - $6.68 Million
148,200 New
148,200 $4.9 Million
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $480,848 - $590,236
-16,400 Reduced 65.86%
8,500 $271,000
Q1 2023

May 15, 2023

SELL
$30.15 - $48.79 $648,225 - $1.05 Million
-21,500 Reduced 46.34%
24,900 $762,000
Q4 2022

Feb 14, 2023

SELL
$36.73 - $51.6 $2.01 Million - $2.82 Million
-54,600 Reduced 54.06%
46,400 $1.81 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $2.01 Million - $3.56 Million
50,600 Added 100.4%
101,000 $4.81 Million
Q2 2022

Aug 15, 2022

BUY
$29.86 - $62.36 $1.5 Million - $3.14 Million
50,400 New
50,400 $1.95 Million
Q1 2022

May 16, 2022

SELL
$53.73 - $82.16 $736,101 - $1.13 Million
-13,700 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $3.52 Million - $5.12 Million
-51,700 Reduced 79.05%
13,700 $1.09 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $1.11 Million - $1.75 Million
13,100 Added 25.05%
65,400 $5.69 Million
Q2 2021

Aug 16, 2021

BUY
$64.12 - $128.71 $3.35 Million - $6.73 Million
52,300 New
52,300 $6.73 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.76B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.